<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04807673</url>
  </required_header>
  <id_info>
    <org_study_id>TianjinCIH20210096</org_study_id>
    <nct_id>NCT04807673</nct_id>
  </id_info>
  <brief_title>Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)</brief_title>
  <acronym>KEYSTONE-002</acronym>
  <official_title>A Multicenter Randomized, Controlled Phase III Clinical Trial of Pembrolizumab Plus Paclitaxel and Cisplatin Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Locally Advanced Esophageal Squamous Cell Carcinoma (KEYSTONE-002)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hebei Medical University Fourth Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liaoning Tumor Hospital &amp; Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tang-Du Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanxi Province Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Jining No.1 People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weifang People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus&#xD;
      paclitaxel, cisplatin as neoadjuvant therapy followed by surgery, and pembrolizumab as&#xD;
      adjuvant therapy, compared with neoadjuvant chemoradiotherapy and surgery for locally&#xD;
      advanced ESCC in multicenter.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preoperative chemoradiotherapy with radical surgery is the recommended treatment for locally&#xD;
      advanced esophageal squamous cell carcinoma (ESCC) in the NCCN guidelines. But many patients&#xD;
      refused or abandon radiotherapy because of the intolerable adverse effects. The purpose of&#xD;
      this study is to evaluate the efficacy and safety of pembrolizumab plus paclitaxel, cisplatin&#xD;
      as neoadjuvant therapy followed by surgery, and pembrolizumab as adjuvant therapy, compared&#xD;
      with neoadjuvant chemoradiotherapy and surgery for locally advanced ESCC in multicenter. The&#xD;
      primary study hypothesis is that Event Free Survival (EFS) is superior with pembrolizumab&#xD;
      plus neoadjuvant chemotherapy compared with neoadjuvant chemoradiotherapy in participants&#xD;
      with ESCC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">May 2028</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event Free Survival (EFS)</measure>
    <time_frame>Up to approximately 2.5 years</time_frame>
    <description>EFS is defined as the time from randomization to the first documented disease progression per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by investigator, or recurrence, or metastasis, or death due to any cause, whichever occurs first. For this analysis, EFS will be assessed in participants with ESCC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>3 and 5 years</time_frame>
    <description>OS is defined as the time from randomization to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival (DFS)</measure>
    <time_frame>3 and 5 years</time_frame>
    <description>Percentage of Participants With DFS, as Assessed by RECIST 1.1. DFS is defined as the time from randomization to the first documented disease progression of local recurrence or distant metastasis or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major pathologic response (MPR)</measure>
    <time_frame>1 month after resection</time_frame>
    <description>MPR is defined as viable tumor comprised ≤ 10% of resected tumor specimens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>1 month after resection</time_frame>
    <description>ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by investigator. For this analysis, ORR will be assessed in all participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic Complete Response (PCR)</measure>
    <time_frame>1 month after resection</time_frame>
    <description>PCR is defined as pT0N0M0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment in perioperation</measure>
    <time_frame>perioperative period</time_frame>
    <description>R0 resection rate， Time of operation， Quantity of bleeding， Thoracic Drainage， Days of Hospitalization， Rate of Operative Complication， Mortality of perioperation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>up to 16 months</time_frame>
    <description>All participants with treatment-related adverse events as assessed by National Cancer Institute Common Terminology Criteria for Adverse Event,Version 4.0(CTC AE4.0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life differences (EORTC QLQ-C30)</measure>
    <time_frame>2.5 years</time_frame>
    <description>The quality of life will be assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer patients (EORTC QLQ-C30) questionnaire. Patients will be invited to finish the questionnaire at the first day of randomization, before surgery and after surgery (3m, 6m, 12m and 24 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life differences (EORTC QLQ-OES18)</measure>
    <time_frame>2.5 years</time_frame>
    <description>The quality of life will be assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer patients (EORTC QLQ-OES18) questionnaire. Patients will be invited to finish the questionnaire at the first day of randomization, before surgery and after surgery (3m, 6m, 12m and 24 months).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">342</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab+ Paclitaxel+Cisplatin+ Surgery+Pembrolizumab (228)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 every 3 weeks (Q3W), paclitaxel 135mg/m^2 IV on Day 2 Q3W, and cisplatin 80 mg/m^2 IV on Day 2 Q3W, a total of three cycles. All treatments will be beginning on Day 1 of each 3-week dosing cycle. Surgery should be done within 4-6 weeks after the last neoadjuvant treatment. After surgery, pembrolizumab 200 mg IV on Day 1 Q3W lasting one year.&#xD;
Surgery: McKeown esophagectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>neoadjuvant chemoradiotherapy+ Surgery (114)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>neoadjuvant chemoradiotherapy 41.4Gy(1.8Gy×23 fractions) with five cycles of TP(Paclitaxel 50mg/m^2 on D1 and Cisplatin 25mg/m^2 D1, repeated every week. Surgery should be done within 4-6 weeks after the last neoadjuvant treatment.&#xD;
Surgery: McKeown esophagectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Neoadjuvant period: pembrolizumab 200mg IV D1, Q3W, and preoperative therapy with three cycles.&#xD;
Adjuvant period: pembrolizumab 200 mg IV D1, Q3W, up to one year, which should be performed within 3-6 weeks after surgery.</description>
    <arm_group_label>Pembrolizumab+ Paclitaxel+Cisplatin+ Surgery+Pembrolizumab (228)</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Neoadjuvant period: paclitaxel 135mg/m^2 IV on Day 2 Q3W, and a total of three cycles.</description>
    <arm_group_label>Pembrolizumab+ Paclitaxel+Cisplatin+ Surgery+Pembrolizumab (228)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Neoadjuvant period: cisplatin 80 mg/m^2 IV on Day 2 Q3W, and a total of three cycles.</description>
    <arm_group_label>Pembrolizumab+ Paclitaxel+Cisplatin+ Surgery+Pembrolizumab (228)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>neoadjuvant chemoradiotherapy</intervention_name>
    <description>neoadjuvant chemoradiotherapy 41.4Gy(1.8Gy×23 fractions) with five cycles of TP(Paclitaxel 50mg/m^2 on D1 and Cisplatin 25mg/m^2 D1, repeated every week</description>
    <arm_group_label>neoadjuvant chemoradiotherapy+ Surgery (114)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed esophageal squamous cell carcinoma;&#xD;
&#xD;
          2. R0 resectable thoracic esophageal cancer, cT1-3N1-2M0, cT2-3N0M0 (AJCC V8 TNM&#xD;
             classification);&#xD;
&#xD;
          3. No suspicious metastatic lymph nodes on the clavicle;&#xD;
&#xD;
          4. Have a performance status of 0 or 1 on the ECOG Performance Scale;&#xD;
&#xD;
          5. Age 18-75 years old, both men and women;&#xD;
&#xD;
          6. Be willing and able to provide written informed consent/assent for the trial;&#xD;
&#xD;
          7. Demonstrate adequate organ function ;&#xD;
&#xD;
          8. Female subject of childbearing potential should have a negative urine or serum&#xD;
             pregnancy within 72 hours before receiving the first dose of study medication. If the&#xD;
             urine test is positive or cannot be confirmed as negative, a serum pregnancy test will&#xD;
             be required;&#xD;
&#xD;
          9. Be willing to provide tissue, blood, and urine samples. Tissue should be from a newly&#xD;
             obtained core or excisional biopsy of a tumor lesion through repeated biopsies.&#xD;
             Newly-obtained is defined as a specimen obtained up to 4 weeks (28 days) before&#xD;
             initiation of treatment on Day 1.&#xD;
&#xD;
         10. Have not received systemic or local treatment for esophageal cancer in the past.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Ineligibility or contraindication for esophagectomy;&#xD;
&#xD;
          2. Prior therapy (operation, radiotherapy, immunotherapy, or chemotherapy) for esophageal&#xD;
             cancer&#xD;
&#xD;
          3. Active autoimmune disease or history of autoimmune disease;&#xD;
&#xD;
          4. Requiring systemic treatment with either corticosteroids or other immunosuppressive&#xD;
             medications;&#xD;
&#xD;
          5. Subjects with a history of symptomatic interstitial lung disease;&#xD;
&#xD;
          6. History of allergy to study drug components;&#xD;
&#xD;
          7. Women must not be pregnant or breast-feeding;&#xD;
&#xD;
          8. Patient has received prior chemotherapy, radiotherapy, target therapy ，and immune&#xD;
             therapy for this malignancy or any other past malignancy;&#xD;
&#xD;
          9. Underlying medical conditions that, in the Investigator's opinion, will make the&#xD;
             administration of study drug hazardous or obscure the interpretation of toxicity or&#xD;
             adverse events.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hongjing Jiang, MD,PhD</last_name>
    <phone>18622221069</phone>
    <email>jianghongjing@tmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaobin Shang, MD,PhD</last_name>
    <phone>18622221071</phone>
    <email>shangxiaobin@tmu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of minimally invasive esophageal surgery, Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongjing Jiang, MD,PhD</last_name>
      <phone>18622221069</phone>
      <email>jianghongjing@tmu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Xiaobin Shang, MD,PhD</last_name>
      <phone>18622221071</phone>
      <email>shangxiaobin@tmu.edu.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Hongjing Jiang, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yin Li, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhigang Li, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hecheng Li, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lijie Tan, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Haiquan Chen, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ziqiang Tian, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jianqun Ma, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yegang MA, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tao Jiang, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shiping Guo, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Haibo Cai, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hengxiao Lu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>esophageal squamous cell carcinoma</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>neoadjuvant therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

